[1. Zuardi AW. History of cannabis as a medicine:a review. Rev Bras Psiquiatr.2006; 28 (2): 153-7.10.1590/S1516-44462006000200015]Search in Google Scholar
[2. Guy G, Whittle BA, Robson PJ. Medical Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press. 2004.]Search in Google Scholar
[3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86: 1646-1647.10.1021/ja01062a046]Search in Google Scholar
[4. Matsuda LA, Bonner TI and Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 1993; 327: 535-550.10.1002/cne.9032704068440779]Search in Google Scholar
[5. Munro S, Thomas KL and Abu-Sharr M. Molecular characterization of a peripheral receptor for cannabinoids. Nature.1993; 365: 61-65.10.1038/365061a07689702]Search in Google Scholar
[6. Iversen L.Cannabis and the brain: Review. Brain.2003 Jun; 126 (6): 1252-70.10.1093/brain/awg14312764049]Search in Google Scholar
[7. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR and Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991; 11: 563-583.10.1523/JNEUROSCI.11-02-00563.1991]Search in Google Scholar
[8. Hohmann AG, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol. 1999; (81): 575-583.10.1152/jn.1999.81.2.57510036261]Search in Google Scholar
[9. Sanudo-Pena MC, Strangman NM, Mackie K, Walker JM and Tsou K. CB1 receptor localization in spinal cord and roots, dorsal root ganglion and peripheral nerve. Acta Pharmacol Sin. 1999; (12): 1115-1120.]Search in Google Scholar
[10. Vaughan VW, Connor M, Bagley EE and Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol. 2000; (57): 288-295.]Search in Google Scholar
[11. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alchol. 2005; Vol.40 (1): 2-14.10.1093/alcalc/agh11015550444]Search in Google Scholar
[12. Wegener N, Koch_M. Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry 2009; 42 (1): 79-8610.1055/s-0029-121634619434559]Search in Google Scholar
[13. Petrosino S., Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 2010; 11: 51-62.]Search in Google Scholar
[14. Matthew J. McFarland, Ekaterina A.Terebova and Eric L. Barker. Detergent-Resistant Membrane Microdomains in the Disposition of the Lipid Signaling Molecule Anandamide. 2005 AAPS National Biotechnology Conference Symposium on Lipidomics. 2006: 95-100.10.1208/aapsj080111275142716584138]Search in Google Scholar
[15. Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patient undergoing cancer chemotherapy. N Z Med J.1980; (91): 449-451.]Search in Google Scholar
[16. McCabe M, Smith FP, Goldberg D, Macdonald J, Wooley PV, Warren R. Efficacy of tetrahydrocannabinol in patient refractory to standard antiemetic therapy. Invest New Drugs. 1988; (6): 243-246.10.1007/BF00175407]Search in Google Scholar
[17. Duran M, Perez E, Abanades S et al. Preliminary efficacy and safety of an oromuscular standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacology. 2010; (70): 656-663.10.1111/j.1365-2125.2010.03743.x]Search in Google Scholar
[18. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manag.1995; (10): 89-97.10.1016/0885-3924(94)00117-4]Search in Google Scholar
[19. Strasser F, Luftner D, et al. Canabis in cachexia study group.Comparasion of orally administreted canabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double- blind, placebo-controlled clinical trial from the Cnnabis in cachexia study group. J Clin Oncol. 2006; (24): 3394-3400.10.1200/JCO.2005.05.1847]Search in Google Scholar
[20. Volicer L,Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patinets with Alzheimer’s disease. Int J Geriatr Psychiatry.1997; (12): 913-919.10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D]Search in Google Scholar
[21. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain. 2007; (133): 210-220.10.1016/j.pain.2007.08.028]Search in Google Scholar
[22. Rog DJ, Nurmikko TJ, Friede T, Young CA.Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology.2005; (65): 812-819.10.1212/01.wnl.0000176753.45410.8b]Search in Google Scholar
[23. Seeling W,Kneer L, Buchele B, et al. Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative paip. Anaesthesist. 2006; (55): 391-400.10.1007/s00101-005-0963-6]Search in Google Scholar
[24. Muller-Vahl KR, Schneider U, Prevedel H, et al. 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:a 6-week randomized trial. J Clin Psychiatry. 2003; (64): 459-465.10.4088/JCP.v64n0417]Search in Google Scholar
[25. Sieradzan KA, Fox SH,Dick J, Brotchie JM. The effects of the cannabinoid receptor agonist nabilone on L-dopa induced dyskinesia in patients with idiopathic Parkinon’s disease. Movement disorders.1998; 13 (Suppl 2).]Search in Google Scholar
[26. Nielsen JB, Crone C., Hultborn H. The spinal pathophysiology of spasticity-from a basic science point of view. Acta Physiologica 2007; 189: 171-180.10.1111/j.1748-1716.2006.01652.x]Search in Google Scholar
[27. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL.Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler.2004; 10 (5): 589-595.10.1191/1352458504ms1085oa]Search in Google Scholar
[28. Crayton HJ, Rossman HS. Clinical Therapeutics 2006; 28 (4): 445-460.]Search in Google Scholar
[29. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess_2003; 7(40): 101-111.10.3310/hta7400]Search in Google Scholar
[30. Bhimani R, Anderson L. Clinical understanding of spasticity: implications for practice. Rehabil Res Pract.2014; 2014:279175. doi: 10.1155/2014/279175.10.1155/2014/279175]Search in Google Scholar
[31. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med._2000; 160 (22): 415-420.10.1001/archinte.160.22.3415]Search in Google Scholar
[32. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev.2003; 4:CD001332.10.1002/14651858.CD001332]Search in Google Scholar
[33. Novotna A, Mares J, Ratcliffe S,et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched- design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011; 2-10.10.1111/j.1468-1331.2010.03328.x]Search in Google Scholar
[34. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis.Nerurology.2004; 62:2098-2100.10.1212/01.WNL.0000127707.07621.72]Search in Google Scholar
[35. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG et al. Endocannabinoids control spasticity in a multiple sclerosis model. Faseb J.2011; 15:300-302.10.1096/fj.00-0399fje]Search in Google Scholar
[36. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a doublelabel in situ hybridization study. Neuroscience.1999; 90(3): 923-931.10.1016/S0306-4522(98)00524-7]Search in Google Scholar
[37. Pertwee RG.Cannabinoid receptors and pain. Prog Neurobiology.2010; 63(5): 569-611.10.1016/S0301-0082(00)00031-9]Search in Google Scholar
[38. Baker D., Pryce G., Jackson SJ., Bolton C., Giovannoni G. The biology that underpins the terapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple sclerosis and Related Disordes 2012; 64: 64-75.10.1016/j.msard.2011.11.00125876933]Search in Google Scholar
[39. Kmietowicz Z. Cannabis based drug is licensed for spasticity in patients with MS. British Medical Journal 2010; 340: c 3363.10.1136/bmj.c336320570870]Search in Google Scholar
[40. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg.Med.Chem. 2015; http://dx.doi.org/10.1016/ j.bmc 2015.01.059.]Search in Google Scholar
[41. Russo E. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011; 163: 1344-1364.10.1111/j.1476-5381.2011.01238.x316594621749363]Search in Google Scholar
[42. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006; 7 (5): 607-15.10.1517/14656566.7.5.60716553576]Search in Google Scholar
[43. Collin C, Ehler E,Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subject with symptoms of spasticity due to multiple sclerosis. Neurol Res.2010; 32(5): 451-459.10.1179/016164109X1259051868566020307378]Search in Google Scholar
[44. Ashton C John. Emerging treatment options for spasticity in multiple sclerosis-clinical utility of cannabinoids. Degenerative Neurological and Neuromuscular Disease. 2011; 15-23.10.2147/DNND.S16081]Search in Google Scholar
[45. Tkaczyk M, Florek E, Piekoszewski W. Marihuana and cannabinoids as medicaments. Przegl Lek. 2012; 69 (10): 1095-97.]Search in Google Scholar
[46. Iversen L. Long-termeffects of exposure to canabis. Curr Opin Pharmacol. 2005;5 (1):69-72 Radhakrishnan R., Wilkinson S. and D Souza DC. Gone to pot-a review of the association between cannabis and psychosis. Frontiers in psychiatry 2014; 54 (5): 1-24.]Search in Google Scholar
[47. Radhakrishnan R., Wilkinson S. and D Souza DC. Gone to pot-a review of the association between cannabis and psychosis. Frontiers in psychiatry 2014; 54 (5): 1-24.]Search in Google Scholar
[48. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008; 178 (13): 1669-1678.10.1503/cmaj.071178241330818559804]Search in Google Scholar
[49. Perez J.Combined cannabinoid therapy via an oromuscular spray. Drugs of Today.2006; 42: 495-503.10.1358/dot.2006.42.8.102151716969427]Search in Google Scholar
[50. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders. CNS Neurosci Ther. 2009; 15: 65-75.10.1111/j.1755-5949.2008.00065.x649402119228180]Search in Google Scholar
[51. Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother.2013; 12: 49-54).10.1586/14737175.2013.86587724289844]Search in Google Scholar
[52. www.mhra.gov.uk. Scheduling of the cannabis-based medicine ‘Sativex’ Accessed in April 2015. Published: 27 March 2013.]Search in Google Scholar
[53. Barbara S. Koppel, John C.M. Brust, Terry F, Jeff Bronstein,Sarah Youssof, Gary Gronseth and David Gloss. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Neurology. 2014; 82_(17):_1556-1563.10.1212/WNL.0000000000000363401146524778283]Search in Google Scholar
[54. Wright S.,Yadav V., Bever C Jr et al. Summary of evidence- based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology._2014; 83 (16):1484-1486.10.1212/01.wnl.0000455935.13606.9125313380]Search in Google Scholar
[55. Potter DJ. A rivew of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal. 2014; 6 (1-2): 31-38.10.1002/dta.153124115748]Search in Google Scholar
[56. www.zdravlje.gov.rs Zakon o psihoaktivnim kontrolisanim supstancama. Službeni glasnik Republike Srbije br.99/10. Accessed in April 2015.]Search in Google Scholar
[57. Arroyo R, Vila C, Dechant KL. Impact of Sativex(®) on_quality of life_and activities of daily living in patients with multiple sclerosis spasticity.J Comp Eff Res. 2014; 3(4):435-44. doi: 10.2217/cer.14.30.10.2217/cer.14.3025275238]Search in Google Scholar
[58. Slof J, Gras A. Sativex in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012; 12 (4): 439-441 10.1586/erp.12.4022681512]Search in Google Scholar